Compare Stocks → [Webinar] Understanding Covered Calls (From OIC) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDigital Media StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare ShareLink copied to clipboard. NASDAQ:CRGXNASDAQ:HLVXNYSE:PRMENASDAQ:RGNX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRGXCARGO Therapeutics$19.17+1.0%$20.23$13.14▼$33.92$754.92MN/A244,261 shs144,468 shsHLVXHilleVax$13.77+11.0%$13.83$9.94▼$20.22$684.64M0.73151,611 shs321,737 shsPRMEPrime Medicine$6.45-1.5%$5.99$4.11▼$17.20$774.19M2.34749,815 shs833,386 shsRGNXREGENXBIO$14.32-3.0%$17.02$11.83▼$28.80$705.40M1.34633,232 shs302,133 shsMetaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRGXCARGO Therapeutics-0.11%-9.01%-6.64%-28.70%+1,897,999,900.00%HLVXHilleVax+2.14%-3.80%-8.89%-35.78%-33.90%PRMEPrime Medicine+1.08%-5.48%+17.17%-18.78%-59.34%RGNXREGENXBIO+2.86%-1.07%-12.30%-40.02%-25.15%Protect Your Bank Account Before It’s Too Late (Ad)For months I’ve been warning about the federal government’s terrifying new program to control every American’s bank account. It gives them the power to monitor every single transaction …Stop right now and do these 3 things to protect yourselfMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCRGXCARGO Therapeutics1.3186 of 5 stars3.50.00.00.02.53.30.0HLVXHilleVax3.6617 of 5 stars3.54.00.00.03.35.00.6PRMEPrime Medicine3.6712 of 5 stars4.40.00.00.03.93.30.6RGNXREGENXBIO4.5867 of 5 stars4.43.00.04.61.33.30.6Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRGXCARGO Therapeutics3.00Buy$29.0051.28% UpsideHLVXHilleVax3.00Buy$29.00110.60% UpsidePRMEPrime Medicine2.83Moderate Buy$15.09133.97% UpsideRGNXREGENXBIO2.83Moderate Buy$38.64169.81% UpsideCurrent Analyst RatingsLatest CRGX, RGNX, HLVX, and PRME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/20/2024PRMEPrime MedicineHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$10.005/16/2024CRGXCARGO TherapeuticsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$34.00 ➝ $32.005/16/2024PRMEPrime MedicineCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$10.005/15/2024HLVXHilleVaxJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$21.00 ➝ $24.005/15/2024RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$36.00 ➝ $38.005/13/2024PRMEPrime MedicineJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$16.00 ➝ $15.005/10/2024HLVXHilleVaxHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$28.005/7/2024PRMEPrime MedicineJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$23.00 ➝ $15.004/23/2024PRMEPrime MedicineWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$12.004/22/2024PRMEPrime MedicineChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$17.004/12/2024RGNXREGENXBIOStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$40.00(Data available from 6/4/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRGXCARGO TherapeuticsN/AN/AN/AN/A$9.84 per shareN/AHLVXHilleVaxN/AN/AN/AN/A$5.48 per shareN/APRMEPrime MedicineN/AN/AN/AN/A$1.37 per shareN/ARGNXREGENXBIO$90.24M7.82N/AN/A$7.09 per share2.02Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRGXCARGO Therapeutics-$98.15MN/A0.00N/AN/AN/AN/AN/A8/13/2024 (Estimated)HLVXHilleVax-$123.57M-$3.30N/AN/AN/AN/A-56.18%-43.75%8/12/2024 (Estimated)PRMEPrime Medicine-$198.13M-$2.17N/AN/AN/AN/A-94.21%-74.52%8/5/2024 (Estimated)RGNXREGENXBIO-$263.49M-$5.88N/AN/AN/A-299.96%-70.72%-41.30%8/7/2024 (Estimated)Latest CRGX, RGNX, HLVX, and PRME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2024Q1 2024CRGXCARGO Therapeutics-$1.05-$0.87+$0.18-$0.87N/AN/A5/10/2024Q1 2024PRMEPrime Medicine-$0.45-$0.44+$0.01-$0.44N/A$0.59 million5/9/2024Q1 2024HLVXHilleVax-$0.84-$0.97-$0.13-$0.97N/AN/A5/8/2024Q1 2024RGNXREGENXBIO-$1.28-$1.38-$0.10-$1.38$23.52 million$15.60 million 3/21/2024Q4 2023CRGXCARGO Therapeutics-$1.62-$1.49+$0.13-$1.49N/AN/A3/20/2024Q4 2023HLVXHilleVax-$0.80-$0.78+$0.02-$0.78N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCRGXCARGO TherapeuticsN/AN/AN/AN/AN/AHLVXHilleVaxN/AN/AN/AN/AN/APRMEPrime MedicineN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRGXCARGO TherapeuticsN/A16.7816.78HLVXHilleVax0.1110.9210.92PRMEPrime MedicineN/A8.918.91RGNXREGENXBION/A3.593.59OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRGXCARGO Therapeutics93.16%HLVXHilleVax86.42%PRMEPrime Medicine70.37%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCRGXCARGO Therapeutics1.38%HLVXHilleVax71.10%PRMEPrime Medicine24.29%RGNXREGENXBIO13.13%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCRGXCARGO Therapeutics11639.38 million38.83 millionN/AHLVXHilleVax9049.72 million14.37 millionNot OptionablePRMEPrime Medicine234120.03 million90.88 millionOptionableRGNXREGENXBIO34449.26 million42.79 millionOptionableCRGX, RGNX, HLVX, and PRME HeadlinesRecent News About These CompaniesMay 31, 2024 | americanbankingnews.comREGENXBIO (NASDAQ:RGNX) Upgraded to "Hold" by StockNews.comMay 30, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Lifted to "Hold" at StockNews.comMay 26, 2024 | americanbankingnews.comREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from AnalystsMay 26, 2024 | marketbeat.comREGENXBIO Inc. (NASDAQ:RGNX) Given Average Rating of "Moderate Buy" by BrokeragesMay 25, 2024 | finance.yahoo.comIt Looks Like REGENXBIO Inc.'s (NASDAQ:RGNX) CEO May Expect Their Salary To Be Put Under The MicroscopeMay 24, 2024 | bovnews.comDon’t be afraid of Regenxbio Inc (RGNX) Stock despite uncertainty and doubtMay 18, 2024 | insidertrades.comKenneth T. Mills Sells 15,000 Shares of REGENXBIO Inc. (NASDAQ:RGNX) StockMay 17, 2024 | insidertrades.comREGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $237,150.00 in StockMay 17, 2024 | marketbeat.comQ2 2024 Earnings Forecast for REGENXBIO Inc. Issued By HC Wainwright (NASDAQ:RGNX)May 16, 2024 | marketbeat.comInsider Selling: REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells 15,000 Shares of StockMay 15, 2024 | markets.businessinsider.comEvaluating Regenxbio: Insights From 9 Financial AnalystsMay 15, 2024 | marketbeat.comHC Wainwright Increases REGENXBIO (NASDAQ:RGNX) Price Target to $38.00May 11, 2024 | finance.yahoo.comAnalysts Have Lowered Expectations For REGENXBIO Inc. (NASDAQ:RGNX) After Its Latest ResultsMay 10, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings: Misses Analyst Revenue and EPS ForecastsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio Amid Promising Drug Developments and Solid FinancialsMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for RegenXBio on Clinical Progress and Promising Therapeutic CandidatesMay 10, 2024 | prnewswire.comREGENXBIO to Participate in Upcoming Investor ConferencesMay 9, 2024 | finance.yahoo.comREGENXBIO Inc. (NASDAQ:RGNX) Q1 2024 Earnings Call TranscriptMay 9, 2024 | marketbeat.comREGENXBIO (NASDAQ:RGNX) Posts Earnings Results, Misses Estimates By $0.10 EPSMay 9, 2024 | finance.yahoo.comRegenxbio Inc (RGNX) Q1 2024 Earnings Call Transcript Highlights: Strategic Progress and Robust ...May 8, 2024 | timesunion.comRegenxbio: Q1 Earnings SnapshotNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCARGO TherapeuticsNASDAQ:CRGXCARGO Therapeutics, Inc., a clinical-stage biotechnology company, develops chimeric antigen receptor (CAR) T-cell therapies for cancer patients. The company's lead program is CRG-022, an autologous CD22 CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in B-cell malignancies. It also develops CRG-023, a tri-specific CAR T product candidate that targets tumor cells with three B-cell antigen targets. The company was formerly known as Syncopation Life Sciences, Inc. and changed its name to CARGO Therapeutics, Inc. in September 2022. CARGO Therapeutics, Inc. was incorporated in 2019 and is headquartered in San Mateo, California.HilleVaxNASDAQ:HLVXHilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines in the United States. It develops HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company was formerly known as MokshaCo, Inc. and changed its name to HilleVax, Inc. in February 2021. HilleVax, Inc. was founded in 2019 and is headquartered in Boston, Massachusetts.Prime MedicineNYSE:PRMEPrime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.REGENXBIONASDAQ:RGNXREGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.